ArticleMedComm2026
Reactive Cutaneous Capillary Endothelial Proliferation in Esophageal Squamous Cell Carcinoma Patients Treated With Camrelizumab-Based Therapy: A Pooled Analysis of Two Phase 3 Trials.
Article in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Open-Label, Active-Controlled, Multi-Center, Phase III Clinical Study of Anti-PD-1 Antibody SHR-1210 vs. Investigator's Choice of Chemotherapy in Subjects With Locally Advanced or Metastatic Esophageal Cancer
PD-1 Antibody SHR-1210 Combined With Paclitaxel and Cisplatin Versus Placebo Combined With Paclitaxel and Cisplatin as First-line Therapy for Advanced Esophageal Cancer: a Randomized, Double-blinded, Controlled, Multi-center Phase III Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common immune-related adverse event associated with camrelizumab and has been linked to favorable outcomes. We conducted a pooled analysis of two phase III randomized trials, ESCORT (NCT03099382) and ESCORT-1st (NCT03691090), to evaluate the clinical characteristics and prognostic relevance of RCCEP in patients with advanced esophageal squamous cell carcinoma (ESCC) receiving camrelizumab-based therapy. A total of 526 patients treated with camrelizumab, either alone or in combination with chemotherapy, were included. Objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were compared according to RCCEP status. Inverse probability of treatment weighting (IPTW) was applied to adjust for baseline imbalances, and a 2-month landmark analysis was performed to reduce lead-time bias. Overall, 420 patients (79.8%) developed RCCEP, mostly grade 1-2 (99.0%), with no RCCEP-related treatment discontinuations. The median onset was 1.18 months, and the duration was 3.12 months. RCCEP-positive patients showed a higher ORR (52.4% vs. 26.4%), longer PFS (5.55 vs. 1.94 months; HR = 0.45), and OS (13.40 vs. 6.11 months; HR = 0.47), consistent after landmark analysis. These findings suggested that RCCEP was frequent yet manageable and may serve as a potential on-treatment biomarker of camrelizumab benefit in ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.